NDONOVO THERAPEUTICS INC - ENDV STOCK NEWS

SofPulse Inc., a subsidiary of Endonovo (ENDV), announced its participation in the US Army Medical Research and Development Command Vendor Day to showcase its FDA-cleared medical device, SofPulse®, for pain management solutions in the VA and DoD systems. The device has shown significant pain reduction benefits and decreased opioid requirements post-surgery. SofPulse® plans to expand its presence in VA/DoD facilities through partnerships and attendance at medical conferences.

Endonovo Therapeutics, Inc. (OTCQB: ENDV) has signed a definitive agreement to sell its SofPulse® business and medical IP to SofPulse, Inc. for a minimum of $50 million. SofPulse, Inc. aims to conduct a capital raise of up to $500,000 through a 506 offering tailored for accredited investors. The company plans to explore growth opportunities and expand its revenue to approximately $100 million by 2025.

Endonovo Therapeutics receives regulatory approval for SofPulse® in Taiwan

Endonovo Therapeutics included on Federal Supply Schedule for SofPulse® PEMF medical devices, paving the way for distribution in government healthcare sectors.

Endonovo Therapeutics, Inc. (OTCQB: ENDV) is advancing its clinical development for treating Traumatic Brain Injury (TBI) with its SofPulse® technology. The company is collaborating with prominent researchers and institutions to evaluate SofPulse®'s effectiveness in alleviating TBI symptoms, including headaches and cognitive impairment. The response from the scientific community has been overwhelmingly positive, indicating significant interest in the technology's potential. The global market for CNS therapeutics is projected to grow from $116.2 billion in 2020 to $214.8 billion by 2028, with the TBI market alone expected to reach $4.5 billion by 2026. Endonovo aims to achieve FDA clearance and reimbursement for SofPulse® treatments, positioning itself for substantial growth in the expanding CNS market.

Endonovo Therapeutics, Inc. (ENDV) announces a partnership with former NFL player David Irving as a brand ambassador for its non-opioid pain relief device, SofPulse^®. Irving will share his experiences using the device, which employs Pulsed Electro Magnetic Field (PEMF) therapy showing positive effects on chronic pain and joint injuries. Irving, who retired due to health issues caused by concussions, emphasizes the need for non-pharmaceutical solutions for pain management. The partnership aims to advance awareness of SofPulse^® among athletes and patients. Endonovo plans to expand research on PEMF therapy, aiming for FDA clearance for treating traumatic brain injury (TBI), post-concussion syndrome (PCS), and other CNS disorders, highlighting the device's potential in the $40.25 billion pain management market.